157 related articles for article (PubMed ID: 26898345)
1. Global proteomic profiling identifies etoposide chemoresistance markers in non-small cell lung carcinoma.
Paul D; Chanukuppa V; Reddy PJ; Taunk K; Adhav R; Srivastava S; Santra MK; Rapole S
J Proteomics; 2016 Apr; 138():95-105. PubMed ID: 26898345
[TBL] [Abstract][Full Text] [Related]
2. Lactate-induced MRP1 expression contributes to metabolism-based etoposide resistance in non-small cell lung cancer cells.
Dong Q; Zhou C; Ren H; Zhang Z; Cheng F; Xiong Z; Chen C; Yang J; Gao J; Zhang Y; Xu L; Fang J; Cao Y; Wei H; Wu Z
Cell Commun Signal; 2020 Oct; 18(1):167. PubMed ID: 33097055
[TBL] [Abstract][Full Text] [Related]
3. Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?
Merk J; Rolff J; Dorn C; Leschber G; Fichtner I
Eur J Cardiothorac Surg; 2011 Jul; 40(1):e29-33. PubMed ID: 21420313
[TBL] [Abstract][Full Text] [Related]
4. Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs.
Pesic M; Markovic JZ; Jankovic D; Kanazir S; Markovic ID; Rakic L; Ruzdijic S
J Chemother; 2006 Feb; 18(1):66-73. PubMed ID: 16572896
[TBL] [Abstract][Full Text] [Related]
5. RB protein status and chemosensitivity in non-small cell lung cancers.
Yamamoto Y; Shimizu E; Masuda N; Takada M; Sone S
Oncol Rep; 1998; 5(2):447-51. PubMed ID: 9468577
[TBL] [Abstract][Full Text] [Related]
6. Sanyang Xuedai enhances the radiosensitivity of human non-small cell lung cancer cells via increasing iNOS/NO production.
Wang L; Xia Y; Chen T; Zeng Y; Li L; Hou Y; Li W; Liu Z
Biomed Pharmacother; 2018 Jun; 102():618-625. PubMed ID: 29602129
[TBL] [Abstract][Full Text] [Related]
7. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
8. Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction.
Böttger F; Schaaij-Visser TB; de Reus I; Piersma SR; Pham TV; Nagel R; Brakenhoff RH; Thunnissen E; Smit EF; Jimenez CR
J Proteomics; 2019 Mar; 196():106-119. PubMed ID: 30710758
[TBL] [Abstract][Full Text] [Related]
9. The association of increased lung resistance protein expression with acquired etoposide resistance in human H460 lung cancer cell lines.
Lee E; Lim SJ
Arch Pharm Res; 2006 Nov; 29(11):1018-23. PubMed ID: 17146971
[TBL] [Abstract][Full Text] [Related]
10. Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells.
Zhan L; Zhang H; Zhang Q; Woods CG; Chen Y; Xue P; Dong J; Tokar EJ; Xu Y; Hou Y; Fu J; Yarborough K; Wang A; Qu W; Waalkes MP; Andersen ME; Pi J
Free Radic Biol Med; 2012 Aug; 53(4):758-68. PubMed ID: 22684020
[TBL] [Abstract][Full Text] [Related]
11. Quantitative proteomic approach to understand metabolic adaptation in non-small cell lung cancer.
Martín-Bernabé A; Cortés R; Lehmann SG; Seve M; Cascante M; Bourgoin-Voillard S
J Proteome Res; 2014 Nov; 13(11):4695-704. PubMed ID: 25029028
[TBL] [Abstract][Full Text] [Related]
12. TopBP1 contributes to the chemoresistance in non-small cell lung cancer through upregulation of p53.
Lv Y; Huo Y; Yu X; Liu R; Zhang S; Zheng X; Zhang X
Drug Des Devel Ther; 2016; 10():3053-3064. PubMed ID: 27729767
[TBL] [Abstract][Full Text] [Related]
13. MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs.
Giaccone G; van Ark-Otte J; Rubio GJ; Gazdar AF; Broxterman HJ; Dingemans AM; Flens MJ; Scheper RJ; Pinedo HM
Int J Cancer; 1996 Jun; 66(6):760-7. PubMed ID: 8647646
[TBL] [Abstract][Full Text] [Related]
14. Absence of death receptor translocation into lipid rafts in acquired TRAIL-resistant NSCLC cells.
Ouyang W; Yang C; Zhang S; Liu Y; Yang B; Zhang J; Zhou F; Zhou Y; Xie C
Int J Oncol; 2013 Feb; 42(2):699-711. PubMed ID: 23258590
[TBL] [Abstract][Full Text] [Related]
15. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway.
Xing Y; Liu Y; Liu T; Meng Q; Lu H; Liu W; Hu J; Li C; Cao M; Yan S; Huang J; Wang T; Cai L
Cell Commun Signal; 2018 Jul; 16(1):43. PubMed ID: 30064446
[TBL] [Abstract][Full Text] [Related]
16. ZNF300 promotes chemoresistance and aggressive behaviour in non-small-cell lung cancer.
Yu S; Ao Z; Wu Y; Song L; Zhang P; Li X; Liu M; Qian P; Zhang R; Li X; Chen Y; Wang X; Wang X; Ruan X; Qian G; Ji F
Cell Prolif; 2020 Nov; 53(11):e12924. PubMed ID: 33078469
[TBL] [Abstract][Full Text] [Related]
17. Identification of DJ-1 as a contributor to multidrug resistance in human small-cell lung cancer using proteomic analysis.
Gao H; Niu Y; Li M; Fang S; Guo L
Int J Exp Pathol; 2017 Apr; 98(2):67-74. PubMed ID: 28580701
[TBL] [Abstract][Full Text] [Related]
18. Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance.
Lin CC; Chen JT; Lin MW; Chan CH; Wen YF; Wu SB; Chung TW; Lyu KW; Chou HC; Chan HL
Toxicol Appl Pharmacol; 2015 Nov; 288(3):359-73. PubMed ID: 26298006
[TBL] [Abstract][Full Text] [Related]
19. 3-O-(Z)-coumaroyloleanolic acid overcomes Cks1b-induced chemoresistance in lung cancer by inhibiting Hsp90 and MEK pathways.
Wang H; Sun M; Guo J; Ma L; Jiang H; Gu L; Wen H; Liao S; Chen J; Zeng B; Li Y; Li Y; Yu X; Feng Y; Zhou Y
Biochem Pharmacol; 2017 Jul; 135():35-49. PubMed ID: 28288818
[TBL] [Abstract][Full Text] [Related]
20. Sequential overexpression of LRP and MRP but not P-gp 170 in VP16-selected A549 adenocarcinoma cells.
Trussardi A; Poitevin G; Gorisse MC; Faroux MJ; Bobichon H; Delvincourt C; Jardillier JC
Int J Oncol; 1998 Sep; 13(3):543-8. PubMed ID: 9683791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
